We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Miniature DNA Sequencing Device Independently Evaluated

By LabMedica International staff writers
Posted on 04 Nov 2015
The performance of a hand held miniature DNA sequencing device has been evaluated by an open, international consortium, and the resulting recommendations and protocols are available. More...


The innovative device opens up new possibilities for using sequencing technology in the field, for example in tracking disease outbreaks, testing packaged food or the trafficking of protected species.

An international team of scientists led by those at Wellcome Trust Center for Human Genetics, Oxford, UK) conducted two sets of ten investigations for the same Escherichia coli isolate (strain K-12 sub-strain MG1655), using a single, shared protocol. The accuracy and reproducibility of the data were consistent between laboratories and of good quality. Each group used the same protocols to obtain total genomic DNA from freshly grown cells, fragment the DNA, prepare libraries, and sequence the libraries using the device.

The device, the MinION (Oxford Nanopore; Oxford, UK) works by detecting individual DNA bases that pass through a nanopore, and unlike existing sequencing technologies, there are few inherent sensing limits on the length of the DNA sequence that it could read at one try. The MinION device was initially made available to thousands of laboratories all over the world, who were inspired to explore the technology and contribute to its development through the MinION Access Program (MAP).

Mark Akeson, PhD, a professor at the University of California Santa Cruz (USA), co-inventor of nanopore sequencing, and consultant to Oxford Nanopore, said, “The device performs well now, particularly for viral and bacterial genomes, so you can ship it anywhere and know you're going to get the same result. We're looking at a democratization of sequencing in the not-so-distant future. That is changing things for people who need to solve critical problems in challenging environments, like tracking Ebola strains during the recent outbreak in West Africa.” The study was published online on October 15, 2015, in the journal F1000Research.

Related Links:

Wellcome Trust Centre for Human Genetics 
Oxford Nanopore 
University of California Santa Cruz 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.